PROCEPT BioRobotics (NASDAQ:PRCT – Get Rating) issued its earnings results on Thursday. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.08, MarketWatch Earnings reports.
PRCT traded up $0.18 during trading on Friday, reaching $35.31. 576,093 shares of the company’s stock were exchanged, compared to its average volume of 288,004. PROCEPT BioRobotics has a one year low of $15.38 and a one year high of $47.73. The company has a current ratio of 20.08, a quick ratio of 19.27 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average price of $32.94 and a two-hundred day moving average price of $30.49.
In other PROCEPT BioRobotics news, major shareholder Global Investors Lp Viking sold 1,249,000 shares of the business’s stock in a transaction that occurred on Friday, March 18th. The shares were sold at an average price of $29.90, for a total transaction of $37,345,100.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
PRCT has been the subject of several analyst reports. Guggenheim dropped their target price on shares of PROCEPT BioRobotics from $55.00 to $40.00 in a research report on Wednesday, March 9th. SVB Leerink upped their price objective on shares of PROCEPT BioRobotics from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 9th. Bank of America lowered their price objective on shares of PROCEPT BioRobotics from $48.00 to $42.00 and set a “buy” rating for the company in a research report on Wednesday, March 9th. Finally, Zacks Investment Research cut shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research report on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $36.83.
About PROCEPT BioRobotics (Get Rating)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
- Get a free copy of the StockNews.com research report on PROCEPT BioRobotics (PRCT)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.